| abstract |
The present invention relates to a fusion protein of an immunoglobulin-like domain that binds to a vascular endothelial growth factor and a placental growth factor as a means of cancer therapy or eye disease treatment. The fusion protein (KP-VR2) of the present invention comprises (a) an immunoglobulin-like domain 2 of VEGFR1; (b) an immunoglobulin-like domain 2 of VEGFR1; And (c) a polypeptide comprising the Fc region of human IgG, having high binding affinity for VEGF and PlGF. In addition, the recombinant fusion protein of the present invention is excellent in the effect of inhibiting migration and invasion of vascular endothelial cells, and has a remarkably excellent proliferation inhibiting effect on various carcinomas and fibroblasts. Therefore, it can be usefully used as a therapeutic agent for cancer diseases and ocular diseases caused by angiogenesis. |